New Sensor Detects Amounts of Radiation Delivered to Breast/Prostate Cancer Patients
AURORA, Colo. – A new sensor device allowing doctors to receive data on the precise amount of radiation being delivered to tumors and surrounding tissue offers cancer patients at the University of Colorado Hospital some peace of mind when it comes knowing their treatment is on target. The DVS (Dose Verification System) Smart Marker is a wireless, implantable radiation sensor which measures radiation doses in both breast and prostate cancer. It also can be used to verify the accurate positioning of the target tissue prior to treatment initiation. The University of Colorado Hospital is the only hospital west of the Mississippi River to provide this level of care.
The device is as small as the length of a dime and can be inserted inside the patient in less than 15 minutes. After each radiation treatment, the DVS provides the physician with a measurement of the actual amounts of radiation delivered to the target tissue. This allows the physician to verify that the treatment plan is delivered accurately, and make any necessary adjustments to the prescribed dose during the radiation therapy treatment course, if indicated. The DVS sensor wirelessly transmits data to a detection paddle held in front of the patient immediately following each radiation treatment.
“The DVS Smart Marker is an important advance in assessing and ensuring that quality radiotherapy is delivered to our patients,” said Dr. Rachel Rabinovitch, professor of Radiation Oncology at the University of Colorado Denver School of Medicine and radiation oncologist at the University of Colorado Cancer Center. “It pairs image guidance with in vivo dosimetry – the ability to actually measure the radiation treatment dose delivered inside the patient.”
“As we move toward more personalized treatment planning for individual patients with cancer, being able to accurately measure the radiation dose delivered will be important in achieving maximal therapeutic effect while minimizing unnecessary injury to the surrounding normal tissues.” Christina Finlayson, MD, director, Dianne O’Connor Thompson Breast Center, and professor of surgery at University of Colorado Denver School of Medicine.
Developed by Sicel Technologies, Inc., the DVS sensors are implanted during a minimally invasive procedure when treating prostate cancer. For breast cancer, the device can be placed at the time of surgery. Data on the amount of radiation being delivered to the target area can be gathered during the course of radiation treatment. If a dose deviation is detected, the treatment plan can be modified and corrected for each individual patient. Accurate delivery of the appropriate dose of radiation is critical for tumor control and cure.
Sicel Technologies, Inc., was founded in 1999 and headquartered in Morrisville, North Carolina. Sicel is a privately held, specialty device company focused on the development of revolutionary therapies that significantly impact the treatment of cancer.
The University of Colorado Hospital is the Rocky Mountain region’s leading academic medical center, and has been recognized as one of the United States’ best hospitals, according to U.S. News & World Report. It is best known as an innovator in patient care and often as one of the first hospitals to bring new medicine to patients’ bedsides. Located at the Anschutz Medical Campus in Aurora, Colo., the hospital’s physicians are all affiliated with the University of Colorado Denver School of Medicine, part of the University of Colorado system. For more information, visit the CU Denver Newsroom.